Pharmaceutical and medicine manufacturing R&D funded by foreign companies

STO-REC-STATMM257ZT1 Official
9 billionUSD

United States · 2023

Pharmaceutical and medicine manufacturing R&D funded by foreign companies in United States stood at 9 billion USD in 2023 (NCSES).

Original source
Publisher
NCSES
Authority tier
T1 Official
Locator
R&D Performance, by Type of R&D, Industry Sector, and Source of Funding
Retrieved
17 Sep 2026
Status
Verified

What the source says

Sixty-six percent of foreign company R&D funding went to three industry groups: pharmaceuticals and medicines (NAICS 3254) ($9 billion), scientific research and development services (NAICS 5417) ($4 billion), and computer and electronic products (NAICS 334) ($4 billion) (table 2).

Verbatim extraction verified: The figure 9 billion USD is directly attested in the quoted passage (R&D Performance, by Type of R&D, Industry Sector, and Source of Funding).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
National Center for Science and Engineering Statistics. (2023). Business R&D Performance in the United States Increases to $722 Billion in 2023. Retrieved September 17, 2026, from https://ncses.nsf.gov/pubs/nsf25353. Via StatOrigin, https://statorigin.org/stat/stat_MM257ZMAAREGBJJTTF3T73T6R0
MLA
National Center for Science and Engineering Statistics. "Business R&D Performance in the United States Increases to $722 Billion in 2023." 2023, https://ncses.nsf.gov/pubs/nsf25353. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_MM257ZMAAREGBJJTTF3T73T6R0.
Chicago
National Center for Science and Engineering Statistics. "Business R&D Performance in the United States Increases to $722 Billion in 2023." 2023. https://ncses.nsf.gov/pubs/nsf25353. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_MM257ZMAAREGBJJTTF3T73T6R0.
BibTeX
@misc{ncses2023pharmaceutical73t6r0, author = {{National Center for Science and Engineering Statistics}}, title = {Business R\&D Performance in the United States Increases to \$722 Billion in 2023}, year = {2023}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_MM257ZMAAREGBJJTTF3T73T6R0}, note = {Original source: https://ncses.nsf.gov/pubs/nsf25353. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATMM257Z T1 Official

Primary Source

Publisher
National Center for Science and Engineering Statistics · homepage ↗
Authority tier
Tier 1 · Multilateral Official
Report
Business R&D Performance in the United States Increases to $722 Billion in 2023
Type
Press release
Published
Locator
R&D Performance, by Type of R&D, Industry Sector, and Source of Funding
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_MM257ZMAAREGBJJTTF3T73T6R0